To investigate the signaling pathways that could sustain resistance to RET inhibition, we generated NSCLC cells resistant to the drugs BLU-667/pralsetinib and LOXO-292/selpercatinib, herein defined as BluR and LoxoR cells, respectively. The gene discussed is RET; the disease is non-small cell lung carcinoma.